Hepatocellular carcinoma tumor cells expressing the engineered tumor-associated antigen (HCC-eTAA)

Hepatocellular carcinoma (HCC) tumor cells expressing engineered tumor-associated antigens represent a cellular target rather than a single molecular entity. In the context of modern oncology, these cells are often the focus of adoptive cell therapies, such as CAR-T or TCR-T cells, which are designed to recognize specific proteins like Glypican-3 (GPC3) or Alpha-fetoprotein (AFP) that have been 'engineered' or selected for high specificity to the tumor microenvironment. These antigens serve as the docking sites for therapeutic agents, facilitating the targeted destruction of malignant hepatocytes while attempting to spare healthy liver tissue. The biological relevance of this target lies in its role in driving liver cancer progression and its utility in overcoming the immune-evasive nature of the HCC tumor microenvironment. Because this entry describes a cell type expressing a variable antigen rather than a specific protein, it is classified as an incorrect molecular target designation in a strict biochemical sense.

Other names

Engineered TAA-expressing HCC cellsHCC cells expressing synthetic tumor antigens

Immunotherapy agents, such as CAR-T cells or monoclonal antibodies, are engineered to recognize and bind to specific antigens (e.g., GPC3, AFP) expressed on the surface of hepatocellular carcinoma cells, leading to direct cell lysis or immune-mediated destruction.